Advanced search
Publication Cover
Molecular & Cellular Oncology Volume 7, 2020 - Issue 3
Submit an article Journal homepage
1,251
Views
2
CrossRef citations to date
0
Altmetric
Author's Views

Protective role of p53 in doxorubicin-induced cardiomyopathy as a mitochondrial disease

Masahiro NishiCardiovascular Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USAORCID Iconhttps://orcid.org/0000-0001-8593-3835View further author information
ORCID Icon,
Ping-Yuan WangCardiovascular Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USAView further author information
&
Paul M. HwangCardiovascular Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected]
View further author information
Article: 1724598 | Received 31 Dec 2019, Accepted 28 Jan 2020, Published online: 23 Feb 2020

References

  • Dhingra R, Margulets V, Chowdhury SR, Thliveris J, Jassal D, Fernyhough P, Dorn GW, Kirshenbaum LA. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proc Natl Acad Sci USA. 2014;111:1–3. doi:10.1073/pnas.1414665111.
  • Fang X, Wang H, Han D, Xie E, Yang X, Wei J, Gu S, Gao F, Zhu N, Yin X, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci USA. 2019;116:2672–3. doi:10.1073/pnas.1821022116.
  • Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, Caldwell RL, Shou W, Field LJ. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation. 2009;119:99–106. doi:10.1161/CIRCULATIONAHA.108.799700.
  • Zhu W, Zhang W, Shou W, Field LJ. P53 inhibition exacerbates late-stage anthracycline cardiotoxicity. Cardiovasc Res. 2014;103:81–89. doi:10.1093/cvr/cvu118.
  • Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 2005;207:436–444. doi:10.1002/path.1863.
  • Kamp WM, Wang PY, Hwang PM. TP53 mutation, mitochondria and cancer. Curr Opin Genet Dev. 2016;38:16–22. doi:10.1016/j.gde.2016.02.007.
  • Li J, Wang PY, Long NA, Zhuang J, Springer DA, Zou J, Lin Y, Bleck CKE, Park JH, Kang JG, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci USA. 2019;116:19626–19634. doi:10.1073/pnas.1904979116.
  • Wang PY, Ma W, Park JY, Celi FS, Arena R, Choi JW, Ali QA, Tripodi DJ, Zhuang J, Lago CU, et al. Increased oxidative metabolism in the Li-Fraumeni syndrome. N Engl J Med. 2013;368:1027–1032. doi:10.1056/NEJMoa1214091.
  • Chandrasekaran K, Anjaneyulu M, Choi J, Kumar P, Salimian M, Ho CY, Russel JW. Role of mitochondria in diabetic peripheral neuropathy: influencing the NAD(+)-dependent SIRT1-PGC-1alpha-TFAM pathway. Int Rev Neurobiol. 2019;145:177–209.
  • Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, Carrero ZI, Ramakrishnan G, Watabe K, Haupt Y, et al. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nat Commun. 2015;6:7389. doi:10.1038/ncomms8389.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.